ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brincidofovir

Also written as “Brincidofovir”, “CMX001” and “SyB V-1901”.

Its studies are mostly in Adenoviridae Infections · Cytomegalovirus Infections · Lymphoma, T-Cell · Smallpox · Kidney Diseases, led by 3 companies.

Drug pageBrincidofovir: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 11, 201019 company-led studies, 1 open or runningNext primary completion: Jan 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticalsits history only140 open or runningphase 3since Jun 11, 2010Oct 23, 2008none ahead
SymBio Pharmaceuticals41 open or runningphase 3since Jan 20, 2026Aug 29, 2020Jan 31, 2028phase 3 · NCT07387367
Emergent BioSolutionsits history only10 open or runningphase 1since Jun 5, 2023Jun 5, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of SymBio Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2020First study: phase 1 study in Drug Drug InteractionFirst studyNCT04542252 · 13 enrolled · Japan
  2. Aug 16, 2022Phase 2 study in Kidney DiseasesNCT05511779 · 1 enrolled · Japan
  3. Dec 24, 2024Phase 2 study in RecurrenceNCT06761677 · 43 enrolled · China, Japan, Singapore
  4. Jan 20, 2026Phase 3 study in Adenoviridae InfectionsPhase 3 reachedNCT07387367 · 180 planned · United States, Austria, Belgium and more

Ahead

  1. Jan 31, 2028Primary completion: phase 3 study in Adenoviridae InfectionsNCT07387367

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 4 SymBio Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07387367Adenoviridae Infections · United States, Austria, Belgium and more3RecruitingJan 31, 2028180
NCT06761677Recurrence · China, Japan, Singapore2SuspendedOct 23, 202743
NCT05511779Kidney Diseases · Japan2TerminatedApr 13, 20231
NCT04542252Drug Drug Interaction · Japan1CompletedDec 22, 202013

How it is read

Names in the registry

  • “Brincidofovir”, 15 entries
  • “CMX001”, 3 entries
  • “SyB V-1901”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.